M
Moumita Saha
Researcher at Indian Institute of Chemical Biology
Publications - 38
Citations - 360
Moumita Saha is an academic researcher from Indian Institute of Chemical Biology. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 6, co-authored 17 publications receiving 121 citations. Previous affiliations of Moumita Saha include Techno India University & Council of Scientific and Industrial Research.
Papers
More filters
Journal ArticleDOI
Amelioration of diabetic nephropathy using pomegranate peel extract-stabilized gold nanoparticles: assessment of NF-κB and Nrf2 signaling system.
Krishnendu Manna,Snehasis Mishra,Moumita Saha,Supratim Mahapatra,Chirag Saha,G B Yenge,Nilesh Gaikwad,Ramkrishna Pal,Dasharath P. Oulkar,Kaushik Banerjee,Krishna Das Saha +10 more
TL;DR: The histological and immunohistochemical findings showed the protective efficacy of PPE-AuNP in reducing STZ-induced glomerular sclerosis and renal fibrosis, and the findings indicate that the use of P pearls might act as an economic therapeutic remedy for alleviating DN.
Journal ArticleDOI
Folic acid-conjugated magnetic mesoporous silica nanoparticles loaded with quercetin: a theranostic approach for cancer management
Snehasis Mishra,Snehasis Mishra,Krishnendu Manna,Utpal Kayal,Moumita Saha,Sauvik Chatterjee,Debraj Chandra,Michikazu Hara,Sriparna Datta,Asim Bhaumik,Krishna Das Saha +10 more
TL;DR: The result suggested that the newly synthesized FA-FE-SBA15QN could be used as a promising chemo theranostic material for the management of carcinoma.
Journal ArticleDOI
Designing of novel zinc(II) Schiff base complexes having acyl hydrazone linkage: study of phosphatase and anti-cancer activities
TL;DR: Three asymmetric tridentate acyl hydrazone Schiff base ligands namely L1, L2 and L3 were prepared via condensation of 4-methoxybenzohydrazide with picolinaldehyde and showed the highest IC50 values for anti-cancer activity towards all three cell lines among the three complexes and complex 3 showed the least activity as observed in the phosphatase activity study.
Journal ArticleDOI
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
Yogiraj Ray,S. R. Paul,Purbita Bandopadhyay,Ranit D'Rozario,Jafar Sarif,Deblina Raychaudhuri,Debaleena Bhowmik,Abhishake Lahiri,Janani Srinivasa Vasudevan,Ranjeet Maurya,Akshay Kanakan,Sachin Sharma,Manoj Kumar,Praveen Singh,Rammohan Roy,Kausik Chaudhury,Rajsekhar Maiti,Saugata Bagchi,Ayan Maiti,Md. Masoom Perwez,A S Mondal,Avinash Tewari,Samik Mandal,Arpan Roy,Moumita Saha,Durba Biswas,Chikam Maiti,Ritwik Bhaduri,S. Chakraborty,Biswanath Sarkar,Anima Haldar,Bibhuti Saha,Shantanu Sengupta,Rajesh Pandey,Shilpak Chatterjee,Prasun Bhattacharya,Sandip Paul,Dipyaman Ganguly +37 more
TL;DR: In this paper , a single center open label phase 2 randomised control trial (Clinical Trial Registry of India No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of passive immunization using convalescent plasma therapy.
Journal ArticleDOI
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
Yogiraj Ray,S. R. Paul,Purbita Bandopadhyay,Ranit D'Rozario,Jafar Sarif,Deblina Raychaudhuri,Debaleena Bhowmik,Abhishake Lahiri,Janani Srinivasa Vasudevan,Ranjeet Maurya,Akshay Kanakan,Sachin Sharma,Manish Kumar,Praveen Singh,Rammohan Roy,Kausik Chaudhury,Rajsekhar Maiti,Saugata Bagchi,Ayan Maiti,Md. Masoom Perwez,A S Mondal,Avinash Tewari,Samik Mandal,Arpan Roy,Moumita Saha,Durba Biswas,Chikam Maiti,Ritwik Bhaduri,S. Chakraborty,Biswanath Sarkar,Anima Haldar,Bibhuti Saha,Shantanu Sengupta,Rajesh Pandey,Shilpak Chatterjee,Prasun Bhattacharya,Sandip Paul,Dipyaman Ganguly +37 more
TL;DR: In this article , a single center open label phase 2 randomised control trial (Clinical Trial Registry of India No. CTRI/2020/05/025209) was done to assess clinical and immunological benefits of passive immunization using convalescent plasma therapy.